Clinical Trials Logo

Filter by:
NCT ID: NCT04106219 Active, not recruiting - Neuroblastoma Clinical Trials

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Start date: June 11, 2020
Phase: Phase 1
Study type: Interventional

The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.

NCT ID: NCT04105608 Completed - Type-2 Diabetes Clinical Trials

GLP-1 and Oxyntomodulin Release in Relation to Diet in Type 2 Diabetes Patients.

VAS
Start date: November 1, 2017
Phase: N/A
Study type: Interventional

The aim of this trial was to assess glycemic control and incretin release in subjects affected by type-2 diabetes, a condition in which GLP-1 release is impaired. It is known that nutrition affects a variety of factors in overall quality of life in diabetes and we hypothesized incretin secretion may improve in acute. As little is known regarding oxyntomodulin secretion in relation to diet, we explored this gut-derived hormone behavior as well. Hence, the administration of two meals was carried out; these were equal in terms of calories but different for macronutrients composition. Appetite rating was assessed as well through a 100-mm horizontal Visual Analogue Scale, either at fasting and for 4 hours once the meal was completed.

NCT ID: NCT04105127 Not yet recruiting - Malocclusion Clinical Trials

Pain and Discomfort With Anterior Versus Posterior Builds-up

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Orthodontic build-ups are made by composite/resin material bonded to the palatal or occlusal surfaces of teeth (usually molars or incisors). Their primary purpose is to prevent heavy contact of the upper teeth with lower fixed appliances in patients with overbite reduction to avoid brackets detachment. These appliances disarticulate the posterior teeth, deprogram the masticatory muscles and allow for eruption, extrusion, and uprighting of the posterior teeth. Build-ups are usually placed in the first months of the fixed orthodontic treatment and contribute to increasing the perception of pain. In the orthodontic daily practice, the pain is the most frequent symptom during treatment and is the one that most frightens/worries the patients. Literature shows that fear of pain is one of the primary reasons that patients fail to seek orthodontic care. Pain has a negative effect on patients' compliance, oral hygiene, and missed appointments. Its effects on patients' daily lives is a major reason for discontinuance of orthodontic treatment. In the literature the prevention of pain and management of orthodontic builds-ups is a poorly analyzed topic, despite being a daily problem in orthodontic clinical practice. So, the aim of the present study is to investigate and analyze the perception of pain and function impairment with different type of build-ups (anterior or posterior) to identify an efficient clinical management protocol and an effective pain and discomfort prevention strategy.

NCT ID: NCT04104776 Recruiting - Endometrial Cancer Clinical Trials

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Start date: September 18, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.

NCT ID: NCT04104763 Completed - Clinical trials for Osteofibrous Dysplasia

Osteofibrous Dysplasia (Kempson-Campanacci's Disease)

DOFOL
Start date: August 8, 2019
Phase:
Study type: Observational

The aim of the present study is to obtain long term follow-up in patients with osteofibrous dysplasia, to assess natural history of the disease, late results of treatment and in particular the potential and risk of progression to adamantinoma.

NCT ID: NCT04104750 Active, not recruiting - Quality of Life Clinical Trials

The Assessment of Fatigue and Quality of Life in Patients With Bone Tumor,

Fatigue-ONCO
Start date: July 26, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of the present observational study is to evaluate and describe the evolution over time of the fatigue and the quality of life of patients with bone tumor, in Rizzoli Orthopedic Institute, Chemotherapy ward, during the chemotherapy treatment and in the first phase of follow-up and to identify possible prognostic factors. Such knowledge is a necessary precondition for identifying patients and the periods most at risk due to the onset of fatigue, so as to be able to hypothesize adequate containment strategies.

NCT ID: NCT04103749 Completed - Clinical trials for Endoscopic Retrograde Cholangiopancreatography

Global Prospective Case Series Using a Single-Use Duodenoscope

Start date: March 22, 2021
Phase: N/A
Study type: Interventional

Confirm procedural performance of the ExaltTM Model D Single-Use Duodenoscope in Endoscopic Retrograde Cholangio-Pancreatography (ERCP) and other duodenoscope-based procedures

NCT ID: NCT04103606 Completed - Eating Disorders Clinical Trials

A Mobile-App Training to Reduce Body Image Disorder Symptoms and Associated Features in Female University Students

Start date: January 30, 2019
Phase: N/A
Study type: Interventional

Body dissatisfaction represents a prevalent condition in young women, and it is associated with low self-esteem, depression, and symptoms of Body Dysmorphic Disorder (BDD) and Eating Disorders (EDs). The aim of the trial is to test the effect of a mobile health application called "GGBI: Positive Body Image" in reducing body dissatisfaction, body dysmorphic disorder/eating disorder symptoms, and associated psychological features in female university students considered at high-risk of developing Body Image Disorders (BIDs). Hypothesis: Participants using "GGBI: Positive Body Image" immediately following baseline assessment (Time 0; T0) (immediate-use App group: iApp) would exhibit greater reduction in body dissatisfaction, body dysmorphic disorder/eating disorder symptoms, and associated psychological features than participants who did not use "GGBI: Positive Body Image" in this phase of the study (delayed-use App group: dApp). Following crossover (Time 1; T1), the investigators expect that participants gains in the iApp group would be maintained at follow-up (Time 2; T2).

NCT ID: NCT04103437 Completed - Injuries Clinical Trials

Evaluation of Harmonicity in Running Gait by the Use of Innovative Techniques of Video Analysis

Start date: November 3, 2018
Phase:
Study type: Observational

This study aims to demonstrate the use of a digital video analysis method to evaluate harmonicity of running gait, through an holistic approach. Furthermore, it explores the association of running gait harmonicity with running velocity and level of training and with running injuries risk .

NCT ID: NCT04102852 Completed - Clinical trials for Ulcerative Colitis Chronic Moderate

Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients

LGGinUC
Start date: September 30, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a randomized double-blind clinical trial that intends to evaluate the efficacy and safety of LGG administration at two different doses, for 1 month, in ulcerative colitis (UC) patients with mild-moderate disease activity in therapy with oral mesalamine. Efficacy of therapy will be evaluated by clinical (Clinical Mayo score, quality of life assessment), endoscopic (Endoscopic Mayo score), histological, biochemical (white cell count, C-reactive protein), and molecular (mucosal colonization of the bacteria, pro- and anti-inflammatory cytokines measurement) parameters. UC patients with mild-moderately active disease despite oral treatment with mesalamine will be assessed at baseline for clinical, endoscopic, histologic inflammatory activity. After a wash-out period of 4 weeks of mesalamine, patients will be randomized to assume a regular (LGG 1.2 × 10^10 Colony Forming Units (CFU)/day, 2 capsules a day) or a double (LGG 2.4 × 10^10 CFU/day, 4 capsules a day) dose of LGG for 1 month. At the end of the treatment, clinical, endoscopic, and histologic inflammatory activity will be evaluated and compared to pre-treatment data. Adhesion and molecular effect of LGG will be also evaluated. Safety will be assessed by weekly phone calls and with direct physical examination at the end of the study period.